The dasatinib drugs market comprises oral medications used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Dasatinib is a kinase inhibitor targeted against Bcr-Abl and Src family kinases approved for the treatment of newly diagnosed adult CML patients. It demonstrates high rates of durable cytogenetic and molecular responses. Dasatinib is generally well tolerated and offers significant advantages over other tyrosine kinase inhibitors by achieving rapid response, excellent long-term survival, and low rates of progression to advanced phases of CML.

The global Dasatinib Drugs Market is estimated to be valued at US$ 1350.6 Mn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends

Increasing prevalence of CML drives the demand for dasatinib drugs. For instance, according to statistics by The Leukemia Lymphoma Society, around 10,000 new cases of CML are reported annually in the United States. Generic availability of dasatinib drugs post patent expiration of branded versions enhances market accessibility and affordability. Additionally, ongoing clinical trials evaluating novel applications and delivery approaches of dasatinib are expected to augment the market growth over the forecast period. For example, a phase II clinical trial is assessing the efficiency and safety of dasatinib in brain metastasis from solid tumors.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/dasatinib-drugs-market-5963

Porter’s Analysis

Threat of new entrants: The threat of new entrants is moderate as Dasatinib Drugs Market requires high RD investment and compliance with stringent regulations which makes the entry barriers moderate for new players.

Bargaining power of buyers: The bargaining power of buyers is high in this market as Dasatinib Drugs are not significantly differentiated and buyers can easily switch between various brands.

Bargaining power of suppliers: The bargaining power of suppliers is moderate as raw material suppliers have limited control over the pricing due to presence of multiple raw material suppliers.

Threat of new substitutes: The threat of new substitutes is low as Dasatinib Drugs have limited substitutes for the treatment of cancer.

Competitive rivalry: The competitive rivalry is high due to presence of large number of established brands competing on the basis of product quality, price and innovation.

Key Takeaways

The global Dasatinib Drugs market is expected to witness high growth. The market in North America region is expected to dominate the global market during the forecast period owing to growing prevalence of cancer and robust healthcare infrastructure in the region.

Regional analysis comprises- North America is expected to hold the largest share in the global Dasatinib Drugs market during the forecast period. This is attributed to increasing healthcare spending and growing adoption of cancer drugs in the region.

Key players operating in the Dasatinib Drugs market are Bristol-Myers Squibb Company, MSN Labs, Lupin, Dr. Reddy’s Laboratories, Gilead Sciences, Inc., Hetero Labs, MANUS AKTTEVA BIOPHARMA LLP, Alembic Pharma, JINLAN Pharm-Drugs Technology Co., Ltd., and Zhejiang Hisun Pharma.